Cargando…

The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting

Intrahepatic cholangiocarcinoma (iCCA) is an anatomically and biologically distinct entity with a rising incidence and a poor prognosis on conventional treatments. Surgery followed by adjuvant chemotherapy is a potentially curative option in resectable cases, while palliative-intent chemotherapy is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salati, Massimiliano, Caputo, Francesco, Baldessari, Cinzia, Carotenuto, Pietro, Messina, Marco, Caramaschi, Stefania, Dominici, Massimo, Bonetti, Luca Reggiani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517413/ https://www.ncbi.nlm.nih.gov/pubmed/34675670 http://dx.doi.org/10.2147/CMAR.S330710

Ejemplares similares

IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting
por: Salati, Massimiliano, et al.
Publicado: (2020)

Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy
por: Salati, Massimiliano, et al.
Publicado: (2022)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
por: Tovoli, Francesco, et al.
Publicado: (2021)

Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma
por: Salati, Massimiliano, et al.
Publicado: (2022)

Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis
por: Garajová, Ingrid, et al.
Publicado: (2023)

Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
por: Garajová, Ingrid, et al.
Publicado: (2023)

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas
por: Pu, Xiaohong, et al.
Publicado: (2023)

Intrahepatic cholangiocarcinoma: Evolving role of neoadjuvant and targeted therapy
por: Ghio, Michael, et al.
Publicado: (2023)

Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis
por: Salati, Massimiliano, et al.
Publicado: (2018)

Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas
por: Pu, Xiaohong, et al.
Publicado: (2021)

A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients
por: Zhang, Lei, et al.
Publicado: (2023)

The role of FGFR inhibitors in the treatment of intrahepatic cholangiocarcinoma—unveiling the future challenges in drug therapy
por: Nishida, Naoshi
Publicado: (2023)

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
por: Mazzaferro, Vincenzo, et al.
Publicado: (2018)

Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

Serum Markers of Intrahepatic Cholangiocarcinoma
por: Malaguarnera, Giulia, et al.
Publicado: (2013)

Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2017)

Erratum to: Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies
por: Lidsky, Michael E., et al.
Publicado: (2022)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

Sprouty2 suppresses progression and correlates to favourable prognosis of intrahepatic cholangiocarcinoma via antagonizing FGFR2 signalling
por: Xu, Yun‐Fei, et al.
Publicado: (2018)

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma
por: Abou-Alfa, Ghassan K., et al.
Publicado: (2022)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
por: Ishido, Shun, et al.
Publicado: (2023)

Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
por: Peng, Min, et al.
Publicado: (2023)

Research of Prostate Cancer Urinary Diagnostic Biomarkers by Proteomics: The Noteworthy Influence of Inflammation
por: Bellei, Elisa, et al.
Publicado: (2023)

Intrahepatic Sarcomatoid Cholangiocarcinoma
por: Malhotra, Shalini, et al.
Publicado: (2010)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Management of Intrahepatic Cholangiocarcinoma
por: Kodali, Sudha, et al.
Publicado: (2021)

Clinical Significance of Molecular Subtypes in Western Advanced Gastric Cancer: A Real-World Multicenter Experience
por: Salati, Massimiliano, et al.
Publicado: (2023)

Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
por: Borad, Mitesh J., et al.
Publicado: (2014)

First proficiency testing for NGS‐based and combined NGS‐ and FISH‐based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma
por: Neumann, Olaf, et al.
Publicado: (2023)

A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma
por: Chu, Zhenzhen, et al.
Publicado: (2023)

The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth
por: Pant, Kishor, et al.
Publicado: (2023)

Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entity
por: Salati, Massimiliano, et al.
Publicado: (2017)

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
por: Gadaleta-Caldarola, Gennaro, et al.
Publicado: (2022)

Two Varieties of Intrahepatic Cholangiocarcinoma
por: Nagorney, David M.
Publicado: (1994)

Intrahepatic Cholangiocarcinoma with Sarcomatous Changes
por: Inoue, Yoshiyuki, et al.
Publicado: (2012)

Intrahepatic cholangiocarcinoma: current perspectives
por: Buettner, Stefan, et al.
Publicado: (2017)

Intratumoral heterogeneity of intrahepatic cholangiocarcinoma
por: Walter, Dirk, et al.
Publicado: (2017)

Molecular heterogeneity in intrahepatic cholangiocarcinoma
por: Ahn, Keun Soo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3p3dl1bhlbtj6g9ehf6h1457d6